← Back to Clinical Trials
Recruiting NCT07594717

NCT07594717 Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07594717
Status Recruiting
Phase
Sponsor Prisma Health-Upstate
Condition Nicotine Use Disoder
Study Type OBSERVATIONAL
Enrollment 70 participants
Start Date 2025-11-12
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Sweet-coolingSweet non-cooling EC flavorTobacco flavor EC

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 70 participants in total. It began in 2025-11-12 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study examines the effects of e-cigarette (EC) flavors among adults with opioid use disorder (OUD) receiving buprenorphine treatment who currently use e-cigarettes. Participants will smell and rate 11 EC flavors based on appeal, sensory characteristics, and likelihood of future use. Researchers will examine how different flavor profiles influence the appeal and reinforcing effects of ECs in this population. The goal is to identify EC flavors that may enhance the acceptability of ECs as a potential harm-reduction strategy among adults with OUD receiving buprenorphine treatment.

Eligibility Criteria

Inclusion Criteria: * Adults aged 21 years or older. * Current e-cigarette users who report e-cigarette use on ≥20 of the past 30 days. * Former daily cigarette smokers who currently smoke on ≤19 days per month and no more than 5 cigarettes per day. * Diagnosed with opioid use disorder (OUD). * Currently receiving buprenorphine treatment for OUD. Exclusion Criteria: \-

Contact & Investigator

Central Contact

Irene Pericot-Valverde, PhD

✉ iperico@clemson.edu

📞 18549998005

Frequently Asked Questions

Who can join the NCT07594717 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Nicotine Use Disoder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07594717 currently recruiting?

Yes, NCT07594717 is actively recruiting participants. Contact the research team at iperico@clemson.edu for enrollment information.

Where is the NCT07594717 trial being conducted?

This trial is being conducted at Greenville, United States.

Who is sponsoring the NCT07594717 clinical trial?

NCT07594717 is sponsored by Prisma Health-Upstate. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology